Home
Live Updates
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma : comparemela.com
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Approval based on results from CheckMate -901, the first Phase 3 trial in this patient population with an immunotherapy-chemotherapy combination to demonstrate survival benefit versus...
Related Keywords
Norway ,
United States ,
China ,
South Korea ,
Japan ,
Taiwan ,
Iceland ,
Netherlands ,
Liechtenstein ,
Bristol Myers Squibb ,
Dana Walker ,
Ono Pharmaceutical Co ,
European Commission ,
Twitter ,
Company Opdivo ,
Youtube ,
European Union ,
Netherlands Cancer Institute ,
European Society Of Medical Oncology ,
Linkedin ,
Exchange Commission ,
Instagram ,
Facebook ,
Bristol Myers ,
European Society ,
Medical Oncology ,
Blinded Independent Central Review ,
Michiel Van ,
Netherlands Cancer ,
Safety Profile ,
Myers Squibb ,
Better Future ,
Fatal Immune Mediated Adverse ,
Full Prescribing Information ,
Allogeneic Hematopoietic Stem Cell ,
Multiple Myeloma ,
Thalidomide Analogue ,
Prescribing Information ,
Ono Pharmaceutical ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
comparemela.com © 2020. All Rights Reserved.